Navigation Links
Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
Date:2/14/2008

EMERYVILLE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss fourth quarter and full year 2007 financial results and provide a business overview on Tuesday, February 19, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and year ended December 31, 2007 will be released earlier that day.

Interested parties may access a live webcast of the presentation at: http://webcast.streamlogics.com/audience/index.asp?eventid=62782 or by dialing 847-413-3238 and using the passcode 20350141. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 20350141 approximately one hour after the teleconference concludes. The replay will be available through March 19, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other tumor types. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vion Pharmaceuticals Holds Special Meeting of Stockholders
3. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
4. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
9. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
10. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/3/2016)... 3, 2016  Discovery Laboratories, Inc. (NASDAQ: ... aerosolized KL4 surfactant therapies for respiratory diseases, today ... an inducement award as a component of employment ... appointed President and Chief Executive Officer.  The award ... February 1, 2016 and granted as an inducement ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier ... the North American healthcare market. , Aerocom Healthcare, LLC will be based in ... will provide new pneumatic tube systems or expand existing systems within the U.S. ...
(Date:2/3/2016)... 2016  Today, Symphony Technology Group (STG) announced the ... leading provider of primary research and analytics-based insight for ... , a global information and technology services company serving ... will be integrated into IMS Health to form a ... capabilities. ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> --> Fourth ... (105.0), up 1,187% compared with fourth quarter of 2014. Gross ... M (loss: 30.0). Earnings per share increased to SEK 6.39 ... M (neg: 74.7). , --> ... SEK 2,900.5 M (233.6), up 1,142% compared with 2014. Gross ...
(Date:2/3/2016)... , Feb. 3, 2016 ... addition of the "Emotion Detection and ... Learning, and Others), Software Tools (Facial Expression, ... End Users,and Regions - Global forecast to ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced ...
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of that Rising Market Are you interested ... analysis forecasts revenues for checkpoint inhibitors. Visiongain,s report ... market, submarket, product and national level. Avoid ... discover what progress, opportunities and revenues those emerging ...
Breaking Biology News(10 mins):